<DOC>
	<DOCNO>NCT01698164</DOCNO>
	<brief_summary>This study evaluate benefit/risk hormone replacement treatment among early menopausal woman China . This multi-centre , random , prospective study .</brief_summary>
	<brief_title>Multi-centre Clinical Trial Hormone Replacement Treatment China</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>go amenorrhea 6 month within 5 year , age 40 60 year , go though postmenopausal symptom , serum E2 concentration &lt; 30pg/ml , serum FSH concentration &gt; 40IU/L . uterine fibroid diameter≥5cm , history diabetes hypertension , history thromboembolism , severe endometriosis , epilepsy , asthma , hyperprolactinemia , first degree relative history breast cancer , severe unstable condition somatic disease , receive HRT past 3 month , drug alcohol abuse past 3 month , endometrial thickness ≥0.5cm withdrawal bleeding , allergic medicine , participate clinical trial within 1 month ago .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>lipid profile</keyword>
	<keyword>coronary heart disease</keyword>
	<keyword>menopausal syndrome</keyword>
	<keyword>MMSE</keyword>
	<keyword>MENQOL</keyword>
	<keyword>HAD</keyword>
</DOC>